Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Yan Chang Author

Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients

Department of Respiratory Medicine, the General Hospital of the PLA Rocket Force, Beijing, China

Biography:

Dr. Yan Chang into Department of Respiratory Medicine at the General Hospital of the PLA Rocket Force, Beijing, China. One of the research work is Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients.

Subjects of specialization: Respiratory Medicine

Research Gate
Get the App